News and features

By studying rare cases of identical twins with leukaemia, scientists have shed new light on the origins of the most common type of childhood cancer – confirming it originates in the womb but that events after birth determine whether or not clinical leukaemia develops.

The Wren Chapel at the Royal Hospital Chelsea was full of guests and famous faces on 6 December, celebrating the 20th Carols from Chelsea service in support of The Institute of Cancer Research, London.

We have picked 10 exciting scientific discoveries from the past academic year that brilliantly showcase the quality, breadth and strategic impact of our research.

Scientists have created a comprehensive tool for predicting an individual’s risk of developing prostate cancer, which they say will help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Henry French gives an update

Scientists and clinicians at The Institute of Cancer Research, London, and from around the world, have shared their condolences and celebrated the many achievements of Professor Daniel Catovsky, who died last week.

The Institute of Cancer Research, London, and biopharmaceutical company Apollo Therapeutics have announced a new collaboration that will advance the development of new cancer drugs, combining the strengths and expertise of both organisations.

Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs.

World-leading cancer researchers announce plans to create a new generation of treatments that target the ecosystems supporting cancer. Their new strategy sees cancer genetics and evolution within complex ecosystems as keys to creating new targeted drugs and immunotherapies. They aim to double survival for people with advanced cancer within a decade by combining existing treatments and using smart dosing strategies

An innovative trial to detect relapse in breast cancer patients with circulating tumour DNA (ctDNA) has opened at our partner hospital, The Royal Marsden NHS Foundation Trust. The TRAK-ER trial, led by researchers at The Royal Marsden and The Institute of Cancer Research, London, will establish a circulating tumour DNA (ctDNA) surveillance programme for over 1,000 patiets with ER positive breast cancer who are currently receiving hormone therapy to reduce their risk of cancer returning.

Personalised cancer medicine start-up Curesponse has become the latest MedTech company to move in at the Innovation Gateway at The London Cancer Hub in Sutton, south London.